Subscribe to our feed.

Purdue technology being commercialized to test cancer drugs' benefit to individual patients

September 30, 2014 — WEST LAFAYETTE, Ind. - An official at a life sciences startup based on a Purdue University innovation says his company may help oncologists see faster than ever which drug therapies will benefit cancer patients and to what extent.Steve Ouellette, co-founder and chief technology officer at KinaSense, said oncologists have no way to predict at the start of therapy which drugs will benefit a patient. An oncologist chooses an option from a group of drugs, administers it and waits to see if it works. Read More

Phase 2b TARGET trial results show improved survival in NSCLC patients

September 27, 2014 — - Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid -- Interim Update of Overall Survival Analysis Shows 30 Percent Reduction of Risk of Death in Pre-Defined Adenocarcinoma Patient Subgroup - - Conference Call/Webcast at 8:30 a.m. EDT Monday, Sept. 29 - Read More